In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Altimmune (ALT – Research Report). The company’s shares ...

William Blair analyst Andy Hsieh initiated coverage of BioAge Labs (BIOA) with a Market Perform rating.Discover the Best Stocks and Maximize ...

Analysts at William Blair upped their FY2025 EPS estimates for Straumann in a report issued on Monday, February 24th. William Blair analyst B. Vazquez now forecasts that the company will post earnings ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Research analysts at William Blair increased their Q1 2025 earnings estimates for shares of Tactile Systems Technology in a note issued to investors on Monday, February 24th. William Blair analyst M.

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The new fund will invest in a niche subset of emerging markets that are 'more challenging for investors to access' ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company ...